Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA110417
Max Phase: Preclinical
Molecular Formula: C16H29N3O6
Molecular Weight: 359.42
Molecule Type: Protein
Associated Items:
ID: ALA110417
Max Phase: Preclinical
Molecular Formula: C16H29N3O6
Molecular Weight: 359.42
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)O)C(C)C
Standard InChI: InChI=1S/C16H29N3O6/c1-8(2)6-11(14(22)19-13(9(3)4)16(24)25)18-15(23)12(7-20)17-10(5)21/h8-9,11-13,20H,6-7H2,1-5H3,(H,17,21)(H,18,23)(H,19,22)(H,24,25)/t11-,12-,13-/m0/s1
Standard InChI Key: ORIIRLCDJGETQD-AVGNSLFASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 359.42 | Molecular Weight (Monoisotopic): 359.2056 | AlogP: -0.76 | #Rotatable Bonds: 10 |
Polar Surface Area: 144.83 | Molecular Species: ACID | HBA: 5 | HBD: 5 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.97 | CX Basic pKa: | CX LogP: -0.74 | CX LogD: -3.91 |
Aromatic Rings: 0 | Heavy Atoms: 25 | QED Weighted: 0.35 | Np Likeness Score: 0.27 |
1. Sawa E, Takahashi M, Kamishohara M, Tazunoki T, Kimura K, Arai M, Miyazaki T, Kataoka S, Nishitoba T.. (1999) Structural modification of Fas C-terminal tripeptide and its effects on the inhibitory activity of Fas/FAP-1 binding., 42 (17): [PMID:10464015] [10.1021/jm980617f] |
Source(1):